{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:43:42Z","timestamp":1792269822950,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"DOI":"10.1007\/s10585-026-10437-7","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:05:15Z","timestamp":1792224315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of local ablative therapy combined with first-line tyrosine kinase inhibitors in epidermal growth factor receptor-mutated oligometastatic non-small cell lung cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9937-3873","authenticated-orcid":false,"given":"Rahul","family":"Bisht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arusha","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban Marcelo Mogrovejo","family":"Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andela","family":"Malaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"10437_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"10437_CR2","doi-asserted-by":"publisher","first-page":"100492","DOI":"10.1016\/j.lanepe.2022.100492","volume":"22","author":"D Debieuvre","year":"2022","unstructured":"Debieuvre D, Molinier O, Falchero L, Locher C, Templement-Grangerat D, Meyer N et al (2022) Lung cancer trends and tumor characteristic changes over 20 years (2000\u20132020): Results of three French consecutive nationwide prospective cohorts\u2019 studies. Lancet Reg Health Europe 22:100492. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100492","journal-title":"Lancet Reg Health Europe"},{"key":"10437_CR3","unstructured":"Clark SB, Alsubait S (2025) Non\u2013Small Cell Lung Cancer. StatPearls Publishing LLC"},{"key":"10437_CR4","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.21037\/tlcr-20-994","volume":"10","author":"MC Tjong","year":"2021","unstructured":"Tjong MC, Louie AV, Iyengar P, Solomon BJ, Palma DA, Siva S (2021) Local ablative therapies in oligometastatic NSCLC-upfront or outback?-a narrative review. Transl Lung Cancer Res 10:3446\u20133456. https:\/\/doi.org\/10.21037\/tlcr-20-994","journal-title":"Transl Lung Cancer Res"},{"key":"10437_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of Four Chemotherapy Regimens for Advanced Non\u2013Small-Cell Lung Cancer. N Engl J Med 346:92\u201398. https:\/\/doi.org\/10.1056\/NEJMoa011954","journal-title":"N Engl J Med"},{"key":"10437_CR6","doi-asserted-by":"publisher","first-page":"102824","DOI":"10.1016\/j.ctrv.2024.102824","volume":"130","author":"C Corvaja","year":"2024","unstructured":"Corvaja C, Passaro A, Attili I, Aliaga PT, Spitaleri G, Signore E, Del et al (2024) Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development. Cancer Treat Rev 130:102824. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102824","journal-title":"Cancer Treat Rev"},{"key":"10437_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y et al (2020) Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC. N Engl J Med 382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"key":"10437_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al (2018) Osimertinib in Untreated EGFR -Mutated Advanced Non\u2013Small-Cell Lung Cancer. N Engl J Med 378:113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"10437_CR9","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-15-0822","volume":"21","author":"DA Palma","year":"2015","unstructured":"Palma DA, Louie AV, Rodrigues GB (2015) New Strategies in Stereotactic Radiotherapy for Oligometastases. Clin Cancer Res 21:5198\u20135204. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0822","journal-title":"Clin Cancer Res"},{"key":"10437_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.5306\/wjco.v10.i10.318","volume":"10","author":"F Cou\u00f1ago","year":"2019","unstructured":"Cou\u00f1ago F, Luna J, Guerrero LL, Vaquero B, Guill\u00e9n-Sacoto MC, Gonz\u00e1lez-Merino T et al (2019) Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions. World J Clin Oncol 10:318\u2013339. https:\/\/doi.org\/10.5306\/wjco.v10.i10.318","journal-title":"World J Clin Oncol"},{"key":"10437_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.23.02075","volume":"43","author":"H Sun","year":"2025","unstructured":"Sun H, Li M, Huang W, Zhang J, Wei S, Yang Y et al (2025) Thoracic Radiotherapy Improves the Survival in Patients with EGFR -Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial. J Clin Oncol 43:412\u2013421. https:\/\/doi.org\/10.1200\/JCO.23.02075","journal-title":"J Clin Oncol"},{"key":"10437_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"10437_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"10437_CR14","doi-asserted-by":"publisher","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. https:\/\/doi.org\/10.1136\/bmj.i4919","DOI":"10.1136\/bmj.i4919"},{"key":"10437_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot\u2013based method of testing and adjusting for publication bias in meta\u2010analysis. Biometrics 56:455\u2013463. https:\/\/doi.org\/10.1111\/j.0006-341X.2000.00455.x","journal-title":"Biometrics"},{"key":"10437_CR16","doi-asserted-by":"publisher","first-page":"101484","DOI":"10.1016\/j.cegh.2023.101484","volume":"25","author":"M Prasad","year":"2024","unstructured":"Prasad M (2024) Introduction to the GRADE tool for rating certainty in evidence and recommendations. Clin Epidemiol Glob Health 25:101484. https:\/\/doi.org\/10.1016\/j.cegh.2023.101484","journal-title":"Clin Epidemiol Glob Health"},{"key":"10437_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"10437_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s41747-020-0145-y","volume":"4","author":"G Di Leo","year":"2020","unstructured":"Di Leo G, Sardanelli F (2020) Statistical significance: p value, 0.05 threshold, and applications to radiomics\u2014reasons for a conservative approach. Eur Radiol Exp 4:18. https:\/\/doi.org\/10.1186\/s41747-020-0145-y","journal-title":"Eur Radiol Exp"},{"key":"10437_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00432-019-03043-6","volume":"146","author":"Y Ni","year":"2020","unstructured":"Ni Y, Ye X, Yang X, Huang G, Li W, Wang J et al (2020) Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment. J Cancer Res Clin Oncol 146:197\u2013203. https:\/\/doi.org\/10.1007\/s00432-019-03043-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"10437_CR20","doi-asserted-by":"publisher","first-page":"e3998","DOI":"10.1097\/MD.0000000000003998","volume":"95","author":"Y Ni","year":"2016","unstructured":"Ni Y, Bi J, Ye X, Fan W, Yu G, Yang X et al (2016) Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study. Medicine 95:e3998. https:\/\/doi.org\/10.1097\/MD.0000000000003998","journal-title":"Medicine"},{"key":"10437_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.lungcan.2019.07.024","volume":"135","author":"F Hu","year":"2019","unstructured":"Hu F, Li C, Xu J, Guo J, Shen Y, Nie W et al (2019) Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients. Lung Cancer 135:138\u2013144. https:\/\/doi.org\/10.1016\/j.lungcan.2019.07.024","journal-title":"Lung Cancer"},{"key":"10437_CR22","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.cllc.2018.09.010","volume":"20","author":"F Hu","year":"2019","unstructured":"Hu F, Xu J, Zhang B, Li C, Nie W, Gu P et al (2019) Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations. Clin Lung Cancer 20:e81\u2013e90. https:\/\/doi.org\/10.1016\/j.cllc.2018.09.010","journal-title":"Clin Lung Cancer"},{"key":"10437_CR23","doi-asserted-by":"publisher","first-page":"766066","DOI":"10.3389\/fonc.2022.766066","volume":"12","author":"X Hu","year":"2022","unstructured":"Hu X, Li H, Kang X, Wang X, Pang H, Liu C et al (2022) First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations. Front Oncol 12:766066. https:\/\/doi.org\/10.3389\/fonc.2022.766066","journal-title":"Front Oncol"},{"key":"10437_CR24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.jtho.2018.05.019","volume":"13","author":"Q Xu","year":"2018","unstructured":"Xu Q, Zhou F, Liu H, Jiang T, Li X, Xu Y et al (2018) Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. J Thorac Oncol 13:1383\u20131392. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.019","journal-title":"J Thorac Oncol"},{"key":"10437_CR25","doi-asserted-by":"publisher","first-page":"109681","DOI":"10.1016\/j.radonc.2023.109681","volume":"184","author":"P Peng","year":"2023","unstructured":"Peng P, Gong J, Zhang Y, Zhou S, Li Y, Han G et al (2023) EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study. Radiother Oncol 184:109681. https:\/\/doi.org\/10.1016\/j.radonc.2023.109681","journal-title":"Radiother Oncol"},{"key":"10437_CR26","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jnci\/djac015","volume":"115","author":"X-S Wang","year":"2023","unstructured":"Wang X-S, Bai Y-F, Verma V, Yu R-L, Tian W, Ao R et al (2023) Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR -Mutated Non-Small Cell Lung Cancer. JNCI: J Natl Cancer Inst 115:742\u2013748. https:\/\/doi.org\/10.1093\/jnci\/djac015","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10437_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00047","author":"MF Chen","year":"2025","unstructured":"Chen MF, Jeng MY, Ma J, Agrawal P, Dunne E, Boe LA et al (2025) Outcomes after radiation for oligoprogressive disease sites in patients with EGFR -mutant lung cancer treated with osimertinib. JCO Precis Oncol https:\/\/doi.org\/10.1200\/PO-25-00047","journal-title":"JCO Precis Oncol"},{"key":"10437_CR28","doi-asserted-by":"publisher","first-page":"102853","DOI":"10.1016\/j.eclinm.2024.102853","volume":"76","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Peng L, Liang F, Chu L, Chu X, Yang X et al (2024) Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial. EClinicalMedicine 76:102853. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102853","journal-title":"EClinicalMedicine"},{"key":"10437_CR29","doi-asserted-by":"publisher","first-page":"103454","DOI":"10.1016\/j.critrevonc.2021.103454","volume":"166","author":"F Papini","year":"2021","unstructured":"Papini F, Sundaresan J, Leonetti A, Tiseo M, Rolfo C, Peters GJ et al (2021) Hype or hope \u2013 Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced\/metastatic NSCLC? Crit Rev Oncol Hematol 166:103454. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103454","journal-title":"Crit Rev Oncol Hematol"},{"key":"10437_CR30","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/JS9.0000000000000339","volume":"109","author":"CH Rim","year":"2023","unstructured":"Rim CH, Cho WK, Park S, Yoon WS, Yang DS (2023) Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis. Int J Surg 109:1006\u20131014. https:\/\/doi.org\/10.1097\/JS9.0000000000000339","journal-title":"Int J Surg"},{"key":"10437_CR31","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","volume":"42","author":"P Iyengar","year":"2024","unstructured":"Iyengar P, Hu C, Gomez DR, Timmerman RD, Simone CB, Robinson CG et al (2024) NRG-LU002: Randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 42:8506. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8506","journal-title":"J Clin Oncol"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-026-10437-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10437-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:03:24Z","timestamp":1792267404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-026-10437-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10437"],"URL":"https:\/\/doi.org\/10.1007\/s10585-026-10437-7","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"56"}}